Precision Peptide Expands Telehealth to 16 Therapies. Repeat Demand Is the Next Test

Updated November 1, 2026 for October 28–29 issuer announcements. The financial periods and October 26 market snapshot below retain their original measurement dates; they are not live November 1 figures.

October 29: Telehealth Expands From Four to Sixteen Prescription Therapies

The Precision Peptide Company’s October 29 release says its U.S. telehealth formulary has grown from four to sixteen prescription therapies across seven therapy areas in less than four months. It describes a total portfolio of 23 products across three formats: needle-free patches, oral and topical formulations, and clinician-prescribed therapies.[11] This is an expansion of the product menu, not a disclosed quadrupling of revenue, patients, prescriptions filled or profit.

The areas named are weight management, performance and growth-hormone support, recovery, longevity and cellular health, immune support, cognitive health and sexual wellness. The release also describes multi-therapy “stacked protocols” managed through a clinician and says prescriptions follow an online assessment reviewed by a U.S.-licensed clinician, with fulfillment by a licensed U.S. 503A pharmacy.[11] Those are issuer descriptions of the operating model; the release does not provide independent patient outcomes or a quantified order backlog.

Our constructive interpretation is a broader customer relationship: a company that previously emphasized a patch line now describes several consumer and prescription formats under one brand. Whether that creates durable value depends on compliant availability, prescribing and fulfillment partners, repeat demand, acquisition costs and cash margins—not simply the number of offerings.

The New Release Explicitly Separates Compounding From FDA Approval

The October 29 release states that the prescription therapies are compounded medications, are not FDA-approved, and have not been evaluated by the FDA for safety, effectiveness or quality. It also says they are not equivalent to, or substitutes for, an FDA-approved product, and that individual therapies remain subject to applicable law and pharmacy supply.[11] A prescription review, a telehealth channel or a licensed pharmacy does not convert the formulations into FDA-approved medicines. The release’s “clinical approval” language refers to clinician review, not approval by a regulator.

These limitations matter commercially as well as medically: prescribing rules, regulatory changes, pharmacy supply and third-party partner performance can constrain the available menu. No treatment recommendation or assumed clinical benefit is made in this report.

October 28: The Company Restated Its Science and Quality Approach

In the intervening October 28 release, Precision highlighted Chief Scientific Officer Justin Kirkland’s three decades of peptide-related experience, a U.S. synthesis and purification process, third-party analytical testing, and its University of Alberta research collaboration.[12] It repeated the previously reported BPC-157 patch purity and content measurements rather than announcing new human efficacy results. Experience, analytical purity and a research relationship can support a development process; they do not establish human delivery, therapeutic benefit, regulatory approval or an approved indication.

The new investment test: future filings need to show whether the expanded platform generates repeat prescription and consumer purchases, better cash conversion and economics that outrun its funding requirements. The financial, dilution and product-stage sections below remain essential context; their measurement dates have not been relabeled as new results.

One Manufacturer Now Covers Four Distinct Product Stages

The October 22 issuer release says its U.S. manufacturer will produce the company’s BPC-157, Thymosin Alpha-1, tirzepatide and GLP3 patch formulations solely for Precision.[1] The business appeal is control over a consistent product line and supply relationship as distribution expands. However, this is an arrangement covering the company’s formulations—not demonstrated ownership of the molecules, a universal patent monopoly or a guarantee that competitors cannot develop other delivery systems.

These stages reflect issuer announcements, not independent clinical verification.[1][2] A company production order is inventory procurement, not a customer purchase order, booked revenue or cash collected. The distinction is especially important for the 20,000 TA1 patches expected next year.

Tirzepatide Testing Expands the Narrative, Not the Approval Status

On October 13, Precision said its tirzepatide transdermal patch had entered formal testing through its U.S. product-development infrastructure; commercial production remains subject to the results.[2] The release does not establish that this is a registered clinical trial, show human bioavailability or efficacy results, or disclose an FDA approval for the patch. Approval of a different medicine containing an ingredient would not establish approval of this delivery product.

Needle-free convenience is the company’s proposed differentiator, not proof that its patch achieves the same exposure, clinical outcomes or safety profile as an approved injectable medicine. We do not assign Precision an assumed share of the broader metabolic-drug market or convert that market’s size into a revenue forecast.

Wholesale Opens Another Door; Reorders Will Show Whether It Works

Precision’s September 29 release opened applications for a U.S. wholesale channel aimed at clinics, medical spas, gyms and specialty retailers, covering its non-prescription range of patches and supplements.[3] Management describes volume pricing, account support and fulfillment from its U.S. operation.[3]

Our constructive interpretation is that wholesale can give an early consumer brand more points of distribution without relying on online advertising alone. The next useful evidence is active purchasing accounts, reorders, customer-acquisition costs and cash receipts—not simply the number of businesses eligible to apply. The release does not quantify a committed wholesale backlog.[3]

The Revenue Base Is Still Small Relative to Spending

Currency basis: the following financial amounts are approximate U.S.-dollar translations of the issuer’s Canadian-dollar statements using the Bank of Canada’s October 26 daily rate. They are comparison figures, not company-reported U.S.-dollar financial statements or historical transaction-date translations.[4][9]

For the quarter ended July 31, 2026, revenue was approximately $45,733, while the net loss was approximately $1.24 million.[4][9] For the nine-month period, revenue was approximately $88,087 and the net loss approximately $2.60 million.[4][9] These figures use net loss, not the larger comprehensive loss that also includes currency translation.

July 31 cash was approximately $1.25 million; operating activities consumed approximately $2.28 million over nine months, while financing activities provided approximately $2.83 million.[4][9] The statements identify a material uncertainty that may cast significant doubt on the company’s ability to continue as a going concern.[4] Later financing and product activity mean this historical balance cannot support a precise current cash-runway claim. The interim statements are unaudited and were not reviewed by the auditor.[4]

Share Issuance Has Already Helped Finance the Rollout

The financial statements show 52,631,207 common shares outstanding at July 31, including 4 million shares issued through a private placement and 7,894,200 shares issued from warrant exercises during the nine-month period.[4] A subsequent-events note reports another 3,005,000 shares issued from warrant exercises, and the September MD&A reports 55,636,207 shares outstanding at its reporting date.[4][5]

The CSE’s October 26 metadata shows 55,836,207 issued shares and 4,813,334 reserved for issuance.[6] Reserved shares are not all already-issued shares or automatically immediately saleable stock. The current CSE figure is later than the financial-statement count; we do not present an unreconciled difference as an exact instrument-by-instrument bridge, and we do not add expired historical warrants back into current supply.

Financing through equity and warrant exercises can fund development without a conventional bank loan, but it also expands the common-share denominator.[4] A larger product line must eventually produce enough economic value to offset that ownership cost. This is why successful commercialization and improving per-share economics must be evaluated together.

Laboratory Purity and an Advisory Vote Are Not Drug Approval

The issuer reports laboratory purity and dose-content measurements for the BPC-157 patch.[1] Those measurements do not by themselves establish delivery through human skin, clinical benefit, long-term safety or regulatory approval.

In July, Precision described a favorable FDA advisory-committee recommendation concerning a potential compounding pathway while explicitly stating that the recommendation was non-binding and subject to final FDA review.[8] A compounding-list discussion is not approval of the company’s finished patch. The FDA’s published safety information separately flags concerns around BPC-157 and thymosin-alpha-1, including immunogenicity, peptide-related impurities and inadequate safety information for proposed uses.[7]

Accordingly, this report does not endorse a treatment, claim that these products are proven safe or effective, or assume that a telehealth channel or manufacturing facility establishes product-level approval. Regulatory changes, enforcement, product-quality failures or an inability to demonstrate reliable delivery could materially weaken the commercial case.

The OTC Chart Still Needs to Repair Its Downtrend

Yahoo’s completed October 26 daily bar records $0.1800, versus $0.2035 on October 23, a calculated decline of approximately 11.55%.[10] The percentage is calculated from those two completed bars, not the provider’s inconsistent summary-change field. These are dated OTC observations, not executable live quotes; the Canadian BPC listing is a separate trading line and currency.

Calculated from the same completed USD daily series, the 5-session simple average is $0.2044, the 20-session average is $0.2412 and the 50-session average is $0.2847.[10] A close below all three does not confirm an upside breakout. Thin OTC trading, wide spreads and vendor coverage differences can make a chart less reliable than a liquid exchange-listed comparison; no exact current float or consolidated-volume claim is made here.

Support: the latest reported low near $0.18 is the immediate stabilization reference.[10] Confirmation: reclaiming the $0.2035–$0.2044 area would improve the short-term repair case, followed by the approximately $0.2412 trend reference.[10] Invalidation: continued trading below the recent-low area would weaken stabilization. These are conditional analytical levels, not promised price targets or personalized trade instructions.

Open the PNGAF OTC chart on TradingView → The external interactive chart updates independently of this article’s dated analysis.

The Next Proof Points Are Deliveries, Sell-Through and Cash

The constructive scenario is concrete: TA1 arrives on the expected timeline; wholesale accounts place repeat orders; the existing patch line produces disclosed revenue and better cash conversion; and newer formulations deliver credible testing evidence within a durable regulatory framework.[1][2][3] That would strengthen the case for a multi-product business rather than a sequence of development headlines.

Our view is that PNGAF offers a clearly defined but high-risk commercialization opportunity. The supply-chain milestone and distribution expansion are worth following, but delays, weak demand, further cash consumption, adverse regulatory outcomes or excessive dilution would undermine the thesis. The next filings need to show that the commercial platform is growing faster than its funding requirements—not just that the list of planned products is getting longer.

Filings, Issuer Releases and Dated Market Sources

1. [1] October 22 issuer filing: exclusive patch manufacturing
2. [2] October 13 issuer filing: tirzepatide testing milestone
3. [3] September 29 issuer filing: U.S. wholesale channel
4. [4] July 31 unaudited interim financial statements, filed September 29
5. [5] September 29 management discussion: liquidity and share data
6. [6] CSE issuer/security metadata captured October 26
7. [7] FDA: potential significant safety risks of compounded peptide substances
8. [8] July 24 issuer filing: advisory vote is not final FDA action
9. [9] Bank of Canada October 26 daily exchange rate; USD translations
10. [10] Yahoo PNGAF completed daily bars through October 26
11. [11] October 29 issuer filing: 16 therapies, 23-product portfolio and compounding limitations
12. [12] October 28 issuer filing: scientific leadership and analytical testing